Modality
Multispecific
MOA
CAR-T BCMA
Target
WRN
Pathway
Neuroinflam
Prostate CaMG
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Apr 2031
Phase 1Current
NCT08919503
18 pts·MG
2023-07→2031-04·Recruiting
NCT05314763
170 pts·Prostate Ca
2020-02→2025-11·Recruiting
188 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-135mo agoPh2 Data· Prostate Ca
2031-04-075.0y awayPh2 Data· MG
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2025-11-13 · 5mo ago
Prostate Ca
Ph2 Data
2031-04-07 · 5.0y away
MG
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08919503 | Phase 1/2 | MG | Recruiting | 18 | 6MWD |
| NCT05314763 | Phase 1/2 | Prostate Ca | Recruiting | 170 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |